Geode Capital Management
IBO

Geode Capital Management’s Impact BioMedical IBO Stock Holding History

Geode Capital Management’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$526K Buy
93,915
+4
+0% +$23 ﹤0.01% 3550
2026
Q2 		$546K Sell
93,911
-616
-0.7% -$4.6K ﹤0.01% 3565
2026
Q1 		$716K Buy
94,527
+88,633
+1,504% +$559K ﹤0.01% 3464
2025
Q4 		$37.6K Buy
5,894
+2,320
+65% +$15.5K ﹤0.01% 4285
2025
Q3 		$30K Sell
3,574
-378
-10% -$3.01K ﹤0.01% 4381
2025
Q2 		$32.3K Buy
3,952
+2,114
+115% +$15K ﹤0.01% 4291
2025
Q1 		$20.2K Buy
1,838
+192
+12% +$4.19K ﹤0.01% 4343
2024
Q4 		$30.1K Buy
+1,646
New +$43.1K ﹤0.01% 4325

Other funds holding IBO

Global Trust Asset Management
Global Trust Asset Management West Palm Beach, Florida $321M AUM 60.77% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
Burk Holdings
Burk Holdings Tulsa, Oklahoma $289M AUM 16.51% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Geode Capital Management's IBO Position: Q3 2026 in Review

Geode Capital Management increased its Impact BioMedical (IBO) stake by 0% in Q3 2026, buying an estimated $23 and bringing the position to 93,915 shares worth $526K. The position accounts for ﹤0.01% of the portfolio, ranked #3550.

Geode Capital Management first reported a position in IBO in Q4 2024 and has held it in 8 quarters since. The position peaked at $716K in Q1 2026. 5 funds tracked by Wall St. Rank hold IBO as of Q3 2026.

  • Geode Capital Management held 93,915 shares of Impact BioMedical worth $526K as of Q3 2026.
  • Geode Capital Management bought 4 Impact BioMedical shares in Q3 2026, an estimated $23.
  • Impact BioMedical made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #3550 holding.
  • Geode Capital Management first reported a position in Impact BioMedical in Q4 2024 and has held it in 8 quarters since.
  • Geode Capital Management's Impact BioMedical position peaked at $716K in Q1 2026.
  • 5 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.